{"width":"100%","url":"https://www.rincos-journal.com/entry/2018/03/10/102300","author_name":"gacharinco","blog_url":"https://www.rincos-journal.com/","provider_url":"https://hatena.blog","provider_name":"Hatena Blog","type":"rich","title":"\u30d4\u30aa\u30b0\u30ea\u30bf\u30be\u30f3\u3082\u308d\u3082\u308d-1\u3010PROactive\u3001\u9aa8\u6298\u30ea\u30b9\u30af\u3001NASH\u3011","image_url":null,"categories":["\u7cd6\u5c3f\u75c5"],"published":"2018-03-10 10:23:00","author_url":"https://blog.hatena.ne.jp/gacharinco/","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Fwww.rincos-journal.com%2Fentry%2F2018%2F03%2F10%2F102300\" title=\"\u30d4\u30aa\u30b0\u30ea\u30bf\u30be\u30f3\u3082\u308d\u3082\u308d-1\u3010PROactive\u3001\u9aa8\u6298\u30ea\u30b9\u30af\u3001NASH\u3011 - \u30ea\u30f3\u30b3&#39;s \u30b8\u30e3\u30fc\u30ca\u30eb\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","blog_title":"\u30ea\u30f3\u30b3's \u30b8\u30e3\u30fc\u30ca\u30eb","description":"\u30d4\u30aa\u30b0\u30ea\u30bf\u30be\u30f3\u306e\u3053\u3068\u3092\u8272\u3005\u3068\u307f\u3066\u3044\u304d\u307e\u3059\u3002 \u307e\u305a\u306f\u3001\u60aa\u540d\u9ad8\u304d(\uff1f)PROactive\u8a66\u9a13\u304b\u3089\u3002 Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactiveStudy (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. (PROactive\u8a66\u9a13\u306b\u304a\u3051\u308b2\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u306e\u5927\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u306e2\u6b21\u4e88\u9632\uff1aRCT) Lancet. 2005\u2026","height":"190","version":"1.0"}